Clinical Trials on Alcoholic Hepatitis in Hong Kong

Total 294 results

Humanity and Health Research Centre

Recruiting

Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease

Chronic Hepatitis B | Nonalcoholic Fatty Liver Disease

China
The University of Hong Kong
Research Grant Council

Recruiting

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B

Cirrhosis | NAFLD | Chronic Hepatitis b | Fibrosis, Liver | Empagliflozin | SGLT2 Inhibitors

Hong Kong
Humanity & Health Medical Group Limited

Recruiting

Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)

Chronic Hepatitis B

Hong Kong
Chinese University of Hong Kong

Completed

An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy

Chronic Hepaititis B

Hong Kong
The University of Hong Kong
Queen Mary Hospital, Hong Kong

Completed

Alcohol Brief Intervention Plus Personalized Mobile Chat-based Intervention to Reduce Alcohol Misuse in an Emergency Department

Alcohol Use Disorder

Hong Kong
Humanity & Health Medical Group Limited

Withdrawn

Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection

HCV Infection

Hong Kong
The University of Hong Kong

Completed

Off Treatment Durability in Chronic Hepatitis B With Good Immune Control

Chronic Hepatitis B

Hong Kong
The University of Hong Kong
Gilead Sciences

Completed

Tenofovir in Asian Chronic Hepatitis B Patients

Chronic Hepatitis B

Hong Kong
Chinese University of Hong Kong

Completed

Serum Hepatitis B Surface Antigen Levels to Guide the Stopping of Entecavir in HBeAg-negative Chronic Hepatitis B

Chronic Hepatitis B

Hong Kong
Humanity and Health Research Centre

Recruiting

Longitudinal Observational Study Of Chinese With NAFLD/NASH

Non-Alcoholic Fatty Liver Disease (NAFLD) | Non-Alcoholic Steatohepatitis (NASH)

Hong Kong
Humanity and Health Research Centre

Recruiting

Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF (SWITAF)

Chronic Hepatitis B

Hong Kong
The University of Hong Kong
Hospital Authority, Hong Kong

Completed

Quality of Life and Health Utility of Patients With CHB Infections

Chronic Hepatitis B Infection

Hong Kong
Humanity and Health Research Centre
University of Maryland; Emory University; Beijing 302 Hospital

Withdrawn

Triple Combination DAAs for Treating HCV GT1b Subjects

Chronic Hepatitis C Infection

Hong Kong
F-star Therapeutics, Inc.
PRA Health Sciences

Terminated

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Hepatitis B | Hepatitis B, Chronic | HBV

Hong Kong
Chinese University of Hong Kong

Withdrawn

Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases

Chronic Hepatitis B

Hong Kong
Chinese University of Hong Kong

Recruiting

SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

Chronic Hepatitis B

Hong Kong
The University of Hong Kong

Recruiting

Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc) (OBI)

Liver Transplant; Complications | Occult Hepatitis B

Hong Kong
GenieBiome Limited

Completed

A Clinical Study to Evaluate the Effect of SIM01 in Female With NAFLD

Non-Alcoholic Fatty Liver Disease

Hong Kong
The University of Hong Kong

Completed

Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study

Exposure to Hepatitis B Virus

Hong Kong
The University of Hong Kong

Completed

Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure

Exposure to Hepatitis B Virus

Hong Kong
The University of Hong Kong

Completed

ID HBV Vaccination With Imiquimod in OBI

Hepatitis B

Hong Kong
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Non-alcoholic Fatty Liver Disease

Hong Kong
Chinese University of Hong Kong
University of Malaya

Terminated

Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients

Immunosuppression | Occult Hepatitis B | Biological Substance; Adverse Effect

Hong Kong
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Completed

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (DASCO)

Chronic Hepatitis C Infection | Hepatitis B Reactivation | HBV Coinfection

China
The University of Hong Kong

Completed

Renoprotective Effects of Telbivudine in Chronic Hepatitis B

Chronic Kidney Diseases | Hepatitis B, Chronic

Hong Kong
The University of Hong Kong
Novartis Pharmaceuticals

Completed

Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)

Chronic Hepatitis B

China
Chinese University of Hong Kong

Not yet recruiting

Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment

Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

Hong Kong
Suzhou Ribo Life Science Co. Ltd.

Completed

A Single and Repeated Dose Escalation of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Chronic Hepatitis b

China
GlaxoSmithKline

Completed

Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

Chronic Hepatitis B

Hong Kong
Humanity and Health Research Centre
Emory University; Beijing 302 Hospital

Completed

Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects

Chronic Hepatitis C Infection

China
Chinese University of Hong Kong

Recruiting

Prospective Evaluation of a Fast-track Treatment Pathway for Patients With Chronic Hepatitis B Under Primary Care

Chronic Hep B

Hong Kong
The University of Hong Kong

Completed

Optimizing HBV Management During Anti-CD20 Antibodies

Hepatitis B | Liver Dysfunction | Immune Suppression

Hong Kong
The University of Hong Kong

Completed

Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong

Hepatitis B Infection

China
The University of Hong Kong

Completed

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load

Hepatitis B, Chronic

China
Chinese University of Hong Kong

Completed

Seroepidemiology of Viral Hepatitis in Hong Kong

Viral Hepatitis

China
Novartis Pharmaceuticals

Completed

Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB

Hepatitis B Virus

China
Chinese University of Hong Kong

Terminated

Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease

Rheumatic Diseases | Hepatitis B, Chronic | Crohn Disease | Ulcerative Colitis | Inflammatory Bowel Disease

Hong Kong
The University of Hong Kong

Recruiting

Nurse-led Alcohol Brief Intervention Plus Mobile Personalized Chat-based Support on Reducing Alcohol Use in University Students

Alcohol Misuse

Hong Kong
Hospital Authority, Hong Kong
Vigconic (International) Ltd.

Completed

A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis

Liver Cirrhosis | Hepatitis B | Hepatitis C

China
Chinese University of Hong Kong

Active, not recruiting

Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir

Chronic Hepatitis B

Hong Kong
The University of Hong Kong
Janssen, LP

Unknown

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Follicular Lymphoma | Chronic Hepatitis B | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Indolent B-cell Lymphomas | Waldenstrom's Macroglobulinaemia

Hong Kong
Chinese University of Hong Kong
GlaxoSmithKline

Completed

Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

Chronic Hepatitis B

China
Humanity and Health Research Centre
Beijing 302 Hospital

Completed

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients

Chronic Hepatitis C Infection

China
Humanity and Health Research Centre
Beijing 302 Hospital

Completed

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients

Chronic Hepatitis C Infection

China
Humanity and Health Research Centre
Beijing 302 Hospital

Completed

SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients

Chronic Hepatitis C Infection

China
The University of Hong Kong

Recruiting

Optimal Exercise Frequency to Reduce Liver Fat in Centrally Obese Adults With Non-Alcoholic Fatty Liver Disease

Obesity | Non-Alcoholic Fatty Liver Disease

Hong Kong
Chinese University of Hong Kong
GlaxoSmithKline; Hoffmann-La Roche

Completed

Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients

Chronic Hepatitis B

China
Chinese University of Hong Kong

Recruiting

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

Cirrhosis Portal

China
Hospital Authority, Hong Kong

Completed

A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers

Neoplasms | Hepatitis B

China
Chinese University of Hong Kong
Hoffmann-La Roche

Completed

Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment

Chronic Hepatitis B

China

Clinical Trials on Alcoholic Hepatitis in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations